International Clinical Trial: A multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the safety and efficacy of CN-105 peptide injection in the treatment of patients with acute ischemic stroke

Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118419) titled 'A multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the safety and efficacy of CN-105 peptide injection in the treatment of patients with acute ischemic stroke' on Feb. 5.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Beijing Tiantan Hospital, Capital Medical University

Condition: Acute ischemic stroke

Intervention: 0.3mg/kg CN-105 peptide group for injection:CN-105 peptide for injection, dose of 0.3mg/kg, intravenous infusion, every 6 hours, total of 13 doses Placebo group:Placebo, intravenous infusion, every 6 hours, total of 13 doses...